GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shanghai Yizhong Pharmaceutical Co 688091.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

36.30

-0.68%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shanghai Yizhong Pharmaceutical Co

Its shares trade on Shanghai under the ticker 688091.SS. It has been listed since 9 September 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥317.1m and net income of CN¥64.1m. At that date it held total assets of CN¥1.53bn and shareholders' equity of CN¥1.43bn.

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of anti-tumor drugs and related pharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-09-09. The firm's main products include paclitaxel micelles, docetaxel micelles and cabazitaxel micelles. Paclitaxel micelles are products under development that have been submitted for registration and marketing applications, and their indications are non-small cell lung cancer. Docetaxel micelles and cabazitaxel micelles are products under development in the pre-clinical research stage.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
9 Sept 2021
Employees
44

Leadership

Pay as last reported

  • Mr. Jinsong ZhouChairman of the Board, General Manager
  • Ms. Zhiyuan ZhangChief Financial Officer
  • Mr. Duan LiDeputy General Manager, Director
  • Ms. Jing SunDeputy General Manager, Director
  • Mr. Wenming ZhangDeputy General Manager
  • Mr. Zhou FangSecretary of the Board
  • Ms. Gairong HuIndependent Director
  • Ms. Yanren XiongIndependent Director
  • Mrs. Aiwu ZhouIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shanghai Yizhong Pharmaceutical's paclitaxel micelles target non-small cell lung cancer with registration submissions.
  • The company's 44 employees focus on anti-tumor drug R&D and manufacturing in Shanghai.
  • Docetaxel micelles and cabazitaxel micelles are in pre-clinical research for anti-tumor applications.

Weaknesses

  • Paclitaxel micelles are still under registration and marketing application process.
  • Docetaxel micelles and cabazitaxel micelles remain in pre-clinical research stage.
  • The company has only 44 employees for R&D and manufacturing operations.

Opportunities

  • Paclitaxel micelles could enter the market for non-small cell lung cancer treatment.
  • Expanding anti-tumor drug portfolio with new micelle products in development.
  • Shanghai's pharmaceutical industry growth supports new drug development.

Threats

  • Competition from established pharmaceutical companies in China.
  • Regulatory delays for paclitaxel micelles marketing approval.
  • Limited workforce may hinder rapid product development and scaling.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.